A Randomized, Double-blind, Placebo-controlled Study Of Safety, Tolerability, And Pharmacokinetics Of Repeated Ascending Subcutaneous Doses Of SAR113244 And Pharmacodynamics Of Single Dose Of SAR113244 In Male And Female Lupus Patient
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 08 Jun 2016
At a glance
- Drugs SAR-113244 (Primary)
- Indications Systemic lupus erythematosus
- Focus Pharmacodynamics
- Sponsors Sanofi
- 02 Jun 2016 Planned End Date changed from 1 Sep 2016 to 1 May 2017.
- 02 Jun 2016 Planned primary completion date changed from 1 Sep 2016 to 1 May 2017.
- 02 Jun 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.